The global lamivudine market​ represents a critical segment within the antiretroviral pharmaceutical industry, characterized by its essential role as a nucleoside reverse transcriptase inhibitor with diverse applications across HIV treatment and hepatitis B management. The market for lamivudine in combination with zidovudine was valued at approximately $1.1 billion in 2024, with projections reaching around $1.9 billion by 2034, reflecting a steady compound annual growth rate (CAGR) of 6.3%​ . Lamivudine, chemically known as (2R,5S)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one (CAS 134678-17-4), has emerged as a fundamental component in first-line antiretroviral regimens and hepatitis B treatment protocols worldwide. This comprehensive analysis examines key purchasing industries, regional procurement patterns, supplier capabilities, and strategic considerations defining the global…